The Primordial team is using the company’s technologies and genetic knowhow to develop advanced and efficient manufacturing methods for the twin carriers of genetic information that are key ingredients in pharmaceutical, diagnostic and R&D products and critical enablers of the biotechnology revolution.
RNA
and
DNA
mRNA Production
Primordial Genetics has developed proprietary RNA polymerases that are being licensed to leading RNA therapeutics and vaccine companies to meet the challenge of manufacturing high-quality, long RNAs for therapeutic and vaccine applications. Messenger RNA (mRNA) based medicines represent a promising new approach to drug and vaccine development.
The leading vaccines against COVID-19 contain mRNA as their active ingredients. The rapid development and distribution of these vaccines has greatly accelerated the commercial development of mRNA-based medicines.
Primordial Genetics’ RNA polymerases offer the following advantages over the standard enzymes currently being used for mRNA manufacturing:
- Dramatic reduction in undesirable side products including double-stranded RNA
- Higher yields
- Higher activity at low temperature (better for maintaining mRNA integrity)
- Higher efficiency at incorporating modified nucleotides
- Higher translatability (reflecting higher overall mRNA quality)
- Higher capping efficiency (capping chemistry dependent)
Learn more about our collection of RNA polymerases that generate superior mRNA.
Oligonucleotide Synthesis
Primordial Genetics is developing an enzymatic oligonucleotide synthesis (EOS) process that has the potential to disrupt and transform the manufacturing of DNA and RNA oligonucleotides, short nucleic acid molecules used in therapeutics, diagnostics, R&D reagents and for data storage.
The EOS process we are developing uses natural nucleotides that are added to a growing DNA strand one by one by specialized DNA polymerases evolved by Primordial Genetics. The use of natural nucleotides makes our process substantially faster, lower-cost and more robust than completing processes being developed or offered by other companies. There is no need for protecting groups and de-blocking steps which streamlines the synthesis, eliminates the possibility of oligonucleotide damage during synthesis and expands the possibilities of custom modifications of the bases and ribose sugars.